-
OCCUPATIONAL OUTCOMES IN PATIENTS WITH TREATMENT-RESISTANT MAJOR DEPRESSIVE DISORDER INITIATING TREATMENT WITH INTRANASAL ESKETAMINE
Aug 11, 2026, 17:16 PM -
A PRAGMATIC CLUSTER-RANDOMIZED REAL-WORLD STUDY OF BIOLOGIC THERAPY IN INFLAMMATORY BOWEL DISEASE IN A US COMMUNITY GASTROENTEROLOGY NETWORK
Aug 11, 2026, 17:16 PM -
EVALUATING AI-ASSISTED TIME-AWARE EVIDENCE MAPPING FOR HEALTH TECHNOLOGY ASSESSMENT: A PILOT REVIEWER AUDIT OF TRACEABILITY, TEMPORAL VALIDITY, AND JURISDICTIONAL ALIGNMENT
Aug 11, 2026, 17:16 PM -
BUDGET IMPACT ANALYSIS OF FITUSIRAN FOR THE TREATMENT OF HEMOPHILIA A AND B IN PEDIATRIC AND ADULT PATIENTS IN SAUDI ARABIA
Aug 11, 2026, 17:16 PM -
METHODOLOGICAL CHARACTERISTICS AND QUALITY OF MODEL-BASED HEALTH ECONOMIC EVALUATIONS FOR CHRONIC HEPATITIS B
Aug 11, 2026, 17:16 PM -
ENGINEERING PERSISTENT CONTEXT FOR REPRODUCIBLE HEOR AI TOOLS
Aug 11, 2026, 17:16 PM -
OVERVIEW OF CHINA AS AN EVOLVING MAJOR PHARMACEUTICAL LAUNCH MARKET
Aug 11, 2026, 17:16 PM -
SSMC BUDGET IMPACT OF ADJUVANT TRASTUZUMAB DERUXTECAN ACROSS THE HER2-POSITIVE EARLY BREAST CANCER PATHWAY: AN AFFORDABILITY MODEL FOR UAE PAYERS
Aug 11, 2026, 17:16 PM -
CONFIGURATION OVER CONTENT: HOW LARGE LANGUAGE MODEL SETTINGS, NOT QUESTION COMPLEXITY, GOVERN REFERENCE FABRICATION IN NARRATIVE-REVIEW-STYLE OUTPUTS
Aug 11, 2026, 17:16 PM -
CROSS-COUNTRY DIFFERENCES IN REAL-WORLD LABORATORY MONITORING INTENSITY AND HEPATOTOXICITY ADVERSE EVENT DETECTION AMONG INITIATORS OF CDK4/6 INHIBITORS FOR ADVANCED BREAST CANCER
Aug 11, 2026, 17:16 PM -
COMPARING NON-CANCER-SPECIFIC SURVIVAL ESTIMATED FROM LIFETABLES AND REPORTED TRIAL DATA: A CASE STUDY FROM EARLY STAGE RESECTED MELANOMA
Aug 11, 2026, 17:16 PM -
HEALTH ECONOMIC IMPACT OF SOFTWARE-ASSISTED BRAIN MRI ON TREATMENT DECISIONS AND OUTCOMES IN RELAPSING-REMITTING MULTIPLE SCLEROSIS: A MICROSIMULATION STUDY
Aug 11, 2026, 17:16 PM -
COMPARISON OF HEALTHCARE COSTS BETWEEN TOCILIZUMAB AND CONVENTIONAL IMMUNOSUPPRESSANTS IN PATIENTS WITH LARGE-VESSEL VASCULITIS: A RETROSPECTIVE STUDY USING CLAIMS DATA IN JAPAN
Aug 11, 2026, 17:16 PM -
ESTIMATING THE PARP INHIBITOR-ELIGIBLE POPULATION AND MARKET OPPORTUNITY IN OVARIAN, BREAST, AND PROSTATE CANCER ACROSS EU15
Aug 11, 2026, 17:16 PM -
INTEGRATING REAL-WORLD PHARMACOGENOMIC EVIDENCE WITH MACHINE LEARNING FOR DRUG RESPONSE PREDICTION: IMPLICATIONS FOR EQUITABLE HEALTH TECHNOLOGY ASSESSMENT
Aug 11, 2026, 17:16 PM -
PRICING, INNOVATION, AND THE VALUE OF LARGER PHASE III TRIALS
Aug 11, 2026, 17:16 PM -
REAL-WORLD TREATMENT PATTERNS AND CLINICAL OUTCOMES IN PREVIOUSLY UNTREATED LOCALLY ADVANCED OR METASTATIC TRIPLE-NEGATIVE BREAST CANCER, BY PD-L1 STATUS: A NORSTELLALINQ US LINKED CLAIMS-EHR STUDY
Aug 11, 2026, 17:16 PM -
EVIDENCE-INFORMED VALIDATION FRAMEWORK FOR GENERATIVE AI-ASSISTED SYSTEMATIC LITERATURE REVIEWS IN HEOR: IMPLICATIONS FOR EUROPEAN HTA AND JCA
Aug 11, 2026, 17:16 PM -
DEVELOPMENT AND VALIDATION OF AN AI-POWERED CLINICAL PHARMACIST ASSISTANT FOR PREDICTING ADVERSE DRUG REACTIONS IN INDIAN HOSPITALS
Aug 11, 2026, 17:16 PM -
HCRU AND DIRECT MEDICAL COSTS IN COPD GOLD 2 - 3 PATIENTS: AN ANALYSIS FROM THE PERSPECTIVE OF CLINICAL EXPERTS IN MEXICO AND ARGENTINA
Aug 11, 2026, 17:16 PM
